Faculty Profile

Alison Mondul received her MSPH in Epidemiology from Emory University in 2002 and her PhD in Cancer Epidemiology from Johns Hopkins University in 2009. She then spent five years as a post-doctoral fellow in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute before joining the University of Michigan as an assistant professor in the Department of Epidemiology.

EPID621: Cancer Epidemiology

EPID 643: Surveillance and Publicly Available Datasets

EPID 709: Fundamentals of Epidemiology

PUBHLTH 401: exploring the public health spectrum of cancer: from prevention to survivorship

• PhD, Cancer Epidemiology, Johns Hopkins University, 2009

• M.S.P.H., Epidemiology, Emory University, 2002

• B.S., Microbiology, University of Illinois at Urbana-Champaign, 1998

• I have devoted my scientific career to studying the role of modifiable risk factors in the etiology of cancer. In particular, I have studied how lifestyle factors (such as use of common medications) and factors related to diet and nutrition (such as micronutrients and lipids) may influence prostate, bladder, and kidney cancers, as well as other genitourinary conditions such as benign prostatic hyperplasia. I have further studied how genetic factors may contribute to or modify these associations. More recently, I have become involved in studying head and neck cancer, which is an exciting area of inquiry as it remains an understudied cancer. In order to study these associations I have used molecular epidemiologic techniques including hypothesis-driven studies of serum biomarkers, genome-wide association studies, and metabolomic profiling.

• Mondul AM, Moore SC, Weinstein SJ, Karoly ED, Sampson JN, Albanes D. Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocopherol, beta-carotene cancer prevention (ATBC) study. Int J Cancer. 2015;137(9):2124-32.
• Alvarez CS, Virani S, Meza R, Rozek R, Sriplung H, Mondul AM. The current and future burden of prostate cancer in Songkhla, Thailand: analysis of incidence and mortality trends, 1990-2030. Journal of Global Oncology. 2018;(4):1-11.
• Yokosawa EB, Arthur AE, Rentschler KM, Wolf GT, Rozek LS, Mondul AM. Vitamin D intake and survival and recurrence in head and neck cancer patients. Laryngoscope. 2018;128(11):E371-76.
• Mondul AM, Joshu CE, Barber JR, Prizment AE, Bhavsar NA, Selvin E, Folsom AR, Platz EA. Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white men in the ARIC Study. Cancer Prev Res. 2018;11(12):779-88.
• Mondul AM, Weinstein SJ, Parisi D, Um CY, McCollough ML, Albanes D. Vitamin D binding protein and risk of renal cell carcinoma in the Cancer Prevention Study-II Cohort. Cancer Epidemiol Biomarkers Prev. 2018;27(10):1203-07.

• American Association for Cancer Research (AACR)